24 research outputs found
Pituitary tumor transforming gene-1 haplotypes and risk of pituitary adenoma: a case-control study
<p>Abstract</p> <p>Background</p> <p>It has been suggested that pituitary adenoma results from accumulation of multiple genetic and/or epigenetic aberrations, which may be identified through association studies. As pituitary tumor transforming gene-1 (<it>PTTG1</it>)/securin plays a critical role in promoting genomic instability in pituitary neoplasia, the present study explored the association of <it>PTTG1 </it>haplotypes with the risk of pituitary adenoma.</p> <p>Methods</p> <p>We genotyped five <it>PTTG1 </it>haplotype-tagging SNPs (htSNP) by PCR-RFLP assays in a case-control study, which included 280 Han Chinese patients diagnosed with pituitary adenoma and 280 age-, gender- and geographically matched Han Chinese controls. Haplotypes were reconstructed according to the genotyping data and linkage disequilibrium status of the htSNPs.</p> <p>Results</p> <p>No significant differences in allele and genotype frequencies of the htSNPs were observed between pituitary adenoma patients and controls, indicating that none of the individual <it>PTTG1 </it>SNPs examined in this study is associated with the risk of pituitary adenoma. In addition, no significant association was detected between the reconstructed <it>PTTG1 </it>haplotypes and pituitary adenoma cases or the controls.</p> <p>Conclusions</p> <p>Though no significant association was found between <it>PTTG1 </it>haplotypes and the risk of pituitary adenoma, this is the first report on the association of individual <it>PTTG1 </it>SNPs or <it>PTTG1 </it>haplotypes with the risk of pituitary adenoma based on a solid study; it will provide an important reference for future studies on the association between genetic alterations in <it>PTTG1 </it>and the risk of pituitary adenoma or other tumors.</p
Signaling pathway networks mined from human pituitary adenoma proteomics data
Abstract Background We obtained a series of pituitary adenoma proteomic expression data, including protein-mapping data (111 proteins), comparative proteomic data (56 differentially expressed proteins), and nitroproteomic data (17 nitroproteins). There is a pressing need to clarify the significant signaling pathway networks that derive from those proteins in order to clarify and to better understand the molecular basis of pituitary adenoma pathogenesis and to discover biomarkers. Here, we describe the significant signaling pathway networks that were mined from human pituitary adenoma proteomic data with the Ingenuity pathway analysis system. Methods The Ingenuity pathway analysis system was used to analyze signal pathway networks and canonical pathways from protein-mapping data, comparative proteomic data, adenoma nitroproteomic data, and control nitroproteomic data. A Fisher's exact test was used to test the statistical significance with a significance level of 0.05. Statistical significant results were rationalized within the pituitary adenoma biological system with literature-based bioinformatics analyses. Results For the protein-mapping data, the top pathway networks were related to cancer, cell death, and lipid metabolism; the top canonical toxicity pathways included acute-phase response, oxidative-stress response, oxidative stress, and cell-cycle G2/M transition regulation. For the comparative proteomic data, top pathway networks were related to cancer, endocrine system development and function, and lipid metabolism; the top canonical toxicity pathways included mitochondrial dysfunction, oxidative phosphorylation, oxidative-stress response, and ERK/MAPK signaling. The nitroproteomic data from a pituitary adenoma were related to cancer, cell death, lipid metabolism, and reproductive system disease, and the top canonical toxicity pathways mainly related to p38 MAPK signaling and cell-cycle G2/M transition regulation. Nitroproteins from a pituitary control related to gene expression and cellular development, and no canonical toxicity pathways were identified. Conclusions This pathway network analysis demonstrated that mitochondrial dysfunction, oxidative stress, cell-cycle dysregulation, and the MAPK-signaling abnormality are significantly associated with a pituitary adenoma. These pathway-network data provide new insights into the molecular mechanisms of human pituitary adenoma pathogenesis, and new clues for an in-depth investigation of pituitary adenoma and biomarker discovery.</p
Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma
The RET proto-oncogene has been identified as the multiple endocrine
neoplasia type 2 disease gene. An association between specific RET
mutation and disease phenotype has been reported. We present the
phenotype-genotype of 12 Greek families with multiple endocrine
neoplasia type 2A (MEN 2A) or familial medullary thyroid carcinoma
(FMTC). Seventy members were studied and DNA analysis for RET mutations
was performed in fifty-eight of them. Exons 10, 11, 13, 14 and 16 of the
RET protooncogene were analyzed by single strand conformation
polymorphism analysis, direct DNA sequencing and/or restriction enzyme
analysis. No mutations of the RET proto-oncogene were identified in 1 of
9 families with MEN 2A and in the 3 families with FMTC. In 7 MEN 2A
families, the mutation was demonstrated in codon 634 and in 1 family it
was demonstrated in codon 620. There was a low frequency, about 8%, of
hyperparathyroidism associated with MEN 2A. The specific causative
mutations for pararthyroid disease were C634R or C634Y. Among the MEN 2A
individuals there was one case with de novo C634R mutation and one case,
C634Y, with cutaneous lichen amyloidosis which predated by 24 years the
diagnosis of MEN 2A. In 2 children who were MEN 2A gene carriers,
microscopic medullary thyroid carcinomas were found. These data show a
low frequency of hyperparathyroidism in our cases and provide further
evidence that individuals with C634R as well as with C634Y mutations of
the RET proto-oncogene could be at risk for parathyroid disease.
Cutaneous lichen amyloidosis could be an early feature of MEN 2A.
Additionally, direct DNA testing provided an opportunity to resect
medullary thyroid carcinoma at an early stage